Olli Keränen

Ahlstrom Oyj engages in the development and manufacture of specialty papers and fiber composites. It operates its business through the following segments: Filtration; Building and Energy; Food and Medical; and Other Operations. The Filtration segment produces air and liquid filtration materials for life science and gas turbine. The Building and Energy segment includes fiber-based materials in wall coverings, floorings, boat hulls, windmill blades, and automotive interiors. The Food and Medical segment comprises of tea bags, coffee filters, meat casing, vegetable parchment, other food packaging materials, medical gowns, drapes, face masks, and sterilization wraps. The Other Operations segment covers financial and tax assets and liabilities; net financing cost; taxes; holding and sales companies income; expense; assets and liabilities; and share of result of associated companies. The company was founded by Antti Ahlström in 1851 and is headquartered in Helsinki, Finland.

Medtentia International Ltd. Oy is a holding company that develops solutions for mitral valve repair based on its proprietary helix ring concept. It is a medical technology company that creates solutions for cardiac interventions. It provides proprietary, helix-shaped products to address the unmet need in cardiac surgery. The company was founded by Dan Mogren and Olli U. Keränen in 2002 by Olli Keränen and is headquartered in Espoo, Finland.

HVR Cardio Oy is a Finnish cardiovascular device company that is developing breakthrough solutions for mitral valve repair based on its proprietary helix technology. The company is based in Espoo, Finland. The company's lead products, CathHELIX® and MAR®, are transcatheter and surgical mitral valve repair devices that are designed to be faster, easier to use, and less invasive without compromising clinical efficacy. The company was founded by Olli Urho Tapani Keränen, and Tom Fleming has been the CEO of the company since 2022.

Novel medical devices for minimal invasive cardiac valve surgery. Medtentia has completed preclinical validation for its first product. Investors Inveni Capital and Industrifonden will take the company through its clinical development phase. Early human trials have been completed successfully Q1 in 2009. Medtentia's technology is patented in USA and patent pending in Europe. Medtentia is a venture-backed medical device company focused on the development of minimally invasive and percutaneous heart valve repair and replacement devices on currently proven therapy. Medtentia will act on a global basis with its core activities and team located to Europe with main office in Helsinki Finland and in the Medicon Valley region of southern Sweden in Lund. Medtentia is currently developing a technology platform of products to enable rapid surgical mitral valve annulus repair and replacement, perform percutaneous mitral repair and replacement, leverage currently accepted therapeutic practice and reduce invasiveness, procedural time and morbidity.